Aryl Heteroaryl Compounds for Apicomplexa Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Apicomplexa-associated diseases, such as malaria, toxoplasmosis, and cryptosporidiosis, are inadequate, necessitating the development of new therapeutic agents effective against these pathogens.
Innovation Solution
A compound with a specific chemical formula, including various aryl, heteroaryl, heterocycloalkyl, and alkylene groups, is provided, which can be used in a pharmaceutical composition to treat Apicomplexa infections by administering an effective amount to a subject in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Apicomplexa-associated diseases are used, then existing therapeutic options are maintained, but treatment effectiveness is inadequate
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (Formula I with various aryl, heteroaryl, heterocycloalkyl, and alkylene groups) to improve treatment effectiveness against Apicomplexa parasites. The chemical parameters of the therapeutic agents are changed to overcome the inadequacy of existing treatments while maintaining targeted anti-parasitic activity.
2Reliability
If new therapeutic agents are developed, then treatment effectiveness improves, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecular structure into distinct substitutable components: core structure with variable groups R1-R6, and interchangeable aryl, heteroaryl, heterocycloalkyl, and alkylene groups. This segmented approach allows systematic development of multiple effective compounds by combining different modular units, managing complexity through structured variation rather than random complexity.
Solution Approach 2:
The patent applies universality by creating a core molecular framework (Formula I) that can serve multiple therapeutic purposes against different Apicomplexa species. The universal core structure with variable substituents provides a multi-functional platform that can treat malaria, toxoplasmosis, and other Apicomplexa-associated diseases, reducing overall development complexity through a single versatile scaffold.
Data Source
AI summary
Disclosed herein, inter alia, are compositions and methods for treating parasitic diseases.